• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Meta-Analysis: Endometrial Thickness Thresholds for Diagnosing Endometrial Malignancies among Postmenopausal Women

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Vitale (AJOG, 2023) evaluated the risk of endometrial carcinoma (EC) and atypical endometrial hyperplasia (AEH) in asymptomatic postmenopausal women based on endometrial thickness

METHODS:

  • Systematic review and diagnostic test accuracy (DTA) meta-analysis
  • Study inclusion criteria
    • Crossover design
    • Evaluated the risk of AEH and EC in postmenopausal asymptomatic women
    • Calculated the diagnostic accuracy of transvaginal ultrasonography thresholds confirmed by histopathologic diagnosis
  • Study design
    • ET thresholds (≥3.0 mm)
      • 3.0 to 5.9 mm
      • 6.0 to 9.9 mm
      • 10.0 to 13.9 mm
      • ≥14.0 mm
    • Quality of studies was assessed
  • Primary outcome
    • Risk of EC and AEH according to each ET threshold
  • Secondary outcomes
    • Positive likelihood ratio (PLR)
    • Negative likelihood ratio (NLR)

RESULTS:

  • 18 studies | 10,334 women
  • Risk for AEH or EC increased relative to women below the cutoff threshold
    • Overall: RR 3.77 (95% CI, 2.26 to 6.32); I2=74%
    • 3.0 and 5.9 mm: RR 5.08 (95% CI, 2.26 to 11.41); I2=0%
    • 6.0 and 9.9 mm: RR 4.34 (95% CI, 1.68 to 11.23); I2=0%
    • 10.0 and 13.9 mm: RR 4.11 (95% CI, 1.55 to 10.87); I2=86%
    • ≥14.0 mm: RR 2.53 (95% CI, 1.04 to 6.16); I2=78%
  • For diagnostic accuracy, the pooled sensitivity decreased from thresholds below 5.9 mm to above 14.0 mm
    • <5.9 mm: RR 0.81 (95% CI, 0.49 to 0.85)
    • ≥14.0 mm: RR 0.28 (95% CI, 0.18 to 0.40)
  • The specificity increased with greater ETs
    • 3.0 and 5.9 mm: RR 0.70 (95% CI, 0.61 to 0.78)
    • ≥14.0 mm: RR 0.86 (95% CI, 0.71 to 0.94)
  • The highest diagnostic odds ratios (OR) were for 3.0 to 5.9 mm and 10.0 to 13.9 mm thresholds
    • 3.0 to 5.9 mm: OR 10 (95% CI, 3 to 41) | AUC 0.81 (95% CI, 0.77 to 0.84)
    • 10.0 to 13.9 mm: OR 11 (95% CI, 2 to 49) | AUC 0.82 (95% CI, 0.79 to 0.86)
  • 3.0 to 5.9 mm cutoff point
    • Increased endometrial carcinoma or atypical endometrial hyperplasia diagnosis within this ET range

CONCLUSION:

  • Both low and high ET thresholds can be successfully used to diagnose EC and AEH in asymptomatic postmenopausal women
    • No substantial risk difference was found compared with higher ultrasonographic thresholds for ET
  • 3.0 to 5.9 mm cutoff results in a lower specificity but higher sensitivity
  •  The authors state

Sensitivity decreases with increased thresholds, whereas specificity increases when shifting from lower to higher cutoffs

Although the use of a threshold between 3.0 and 5.9 mm had the highest sensitivity, this should be balanced with cost and patient convenience as screening protocols when deciding which asymptomatic postmenopausal women with increased ET should have a subsequent biopsy 

Learn More – Primary Sources:

Risk of endometrial cancer in asymptomatic postmenopausal women in relation to ultrasonographic endometrial thickness: systematic review and diagnostic test accuracy meta-analysis

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

What is the Association Between Postmenopausal Bleeding and Risk for Endometrial Cancer?
Is There Any Benefit to Diagnosing Endometrial Cancer in Asymptomatic Women?
Atypical Hyperplasia Confined to Polyps: What is the Incidence of Endometrial Carcinoma?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site